CT TAVR Abdomen Study
Launched by UNIVERSITY OF MARYLAND, BALTIMORE · Feb 24, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The CT TAVR Abdomen Study is exploring a new way to perform CT scans for patients who need a transcatheter aortic valve replacement (TAVR). This study is important because it looks at using a lower dose of iodine-based contrast during the scan, which can help during times when there is a shortage of this contrast material. By reducing the amount of contrast used, the study aims to make the procedure safer, especially for patients with kidney issues, and potentially save costs for hospitals.
To be eligible for this study, participants need to be scheduled for an abdominal CT scan before their TAVR procedure. However, individuals who cannot have a CT scan, have an allergy to the contrast that isn’t managed with medication, or have significant kidney problems (with a GFR of less than 30) will not be able to join. If you participate, you can expect to undergo a CT scan with less contrast than usual, and the results will help determine if this method is effective for planning TAVR surgeries.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • scheduled to receive TAVR abdominal CT
- Exclusion Criteria:
- • cannot undergo CT scan
- • Allergy to intravenous contrast not controlled by steroids or benadryl
- • GFR\<30
About University Of Maryland, Baltimore
The University of Maryland, Baltimore (UMB) is a leading academic institution dedicated to advancing healthcare through innovative research and clinical trials. As a prominent sponsor of clinical studies, UMB leverages its extensive resources and expertise across various disciplines, including medicine, pharmacy, nursing, and social work, to contribute to groundbreaking discoveries and improve patient outcomes. Committed to ethical research practices and collaboration, UMB fosters an environment that promotes the translation of scientific knowledge into real-world applications, ultimately enhancing the well-being of diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Baltimore, Maryland, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials